补肾养肝汤治疗早期糖尿病肾病临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R587.2

基金项目:


Clinical Study on Bushen Yanggan Tang for Early-Stage Diabetic Kidney Disease
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察补肾养肝汤治疗肝肾阴虚证早期糖尿病肾病(DKD) 的临床疗效。方法:将258 例肝肾阴虚证DKD 患者随机分为研究组和对照组各129 例。对照组给予常规控制血糖、血压治疗,研究组在对照组的基础上加服补肾养肝汤治疗。2 组均连续治疗3 个月,观察比较2 组治疗前后中医证候积分,同时对2 组血糖水平、肾功能损伤程度以及炎症因子水平进行比较分析。结果:研究组总有效率为93.80%,对照组为83.72%,2 组比较,差异有统计学意义(P<0.05)。治疗前,2 组中医证候积分比较,差异无统计学意义(P>0.05);治疗后,2 组中医证候积分均较治疗前降低(P<0.05),且研究组证候积分低于对照组(P<0.05)。治疗前,2 组空腹血糖(FBG)、餐后2 h 血糖(P2hBG)、糖化血红蛋白(HbA1c) 比较,差异无统计学意义(P>0.05);治疗后,2 组FBG、P2hBG、HbA1c 水平较治疗前降低(P<0.05),且研究组各项指标均低于对照组(P<0.05)。治疗前,尿微量白蛋白(mAlb)、血尿酸(UA) 水平比较,差异无统计学意义(P>0.05);治疗后,2 组mAlb、UA 水平均较治疗前降低(P<0.05),且研究组mAlb、UA 水平低于对照组(P<0.05)。治疗前,2 组超敏C-反应蛋白(hs-CRP)、降钙素原(PCT)、转化生长因子-β1(TGF-β1) 水平比较,差异无统计学意义(P>0.05);治疗后,2 组hs-CRP、PCT、TGF-β1 水平均较治疗前降低(P<0.05),且研究组各项指标均低于对照组(P<0.05)。结论:补肾养肝汤治疗早期糖尿病肾病能提高临床疗效,有效控制患者血糖水平,降低尿白蛋白,改善机体微炎症状态及肾功能损伤。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Bushen Yanggan tang on the treatment of early- stage diabetic kidney disease(DKD) with liver-kidney yin deficiency syndrome. Methods:A total of 258 DKD patients with liver-kidney yin deficiency syndrome were randomly divided into the study group and the control group,129 cases in each group.The control group was treated with routine control of blood glucose and blood pressure,while the study group was treated with Bushen Yanggan tang on the basis of the control group.The two groups were treated for three months. The Chinese medicine syndrome scores before and after treatment were observed and compared between the two groups. Meanwhile,the levels of blood glucose,kidney function injury and inflammatory factors in the two groups were compared and analyzed. Results: The total effective rate was 93.80% in the study group and 83.72% in the control group,the difference being significant(P< 0.05). Before treatment, there was no significant difference in the comparison of the Chinese medicine syndrome score between the two groups(P>0.05). After treatment,the Chinese medicine syndrome scores in both groups were decreased when compared with those before treatment(P<0.05),and the syndrome score in the study group was lower than that in the control group(P < 0.05). Before treatment , there was no significant difference in the comparison of fasting blood glucose(FBG), 2 h postprandial blood glucose(P2hBG) and HbA1c between the two groups(P>0.05). After treatment, the levels of FBG,P2hBG and HbA1c in the two groups were decreased when compared with those before treatment(P<0.05), and the above levels in the study group were lower than those in the control group(P<0.05). Before treatment,there was no significant difference in the comparison of the levels of urinary microalbumin(mAlb) and serum uric acid(UA) between the two groups(P>0.05). After treatment, the levels of mAlb and UA in both groups were decreased when compared with those before treatment(P<0.05),and the above two levels in the study group were lower than those in the control group(P<0.05). Before treatment,there was no significant difference in the comparison of the levels of Hypersensitive C-reactive protein(hs- CRP),procalcitonin(PCT) and transforming growth factor-β1(TGF-β1)(P>0.05). After treatment,the levels of hs-CRP,PCT and TGF-β1 in both groups were decreased when compared with those before treatment(P<0.05),and the above levels in the study group were lower than those in the control group(P<0.05). Conclusion: Bushen Yanggan tang for early- stage DKD,can improve the clinical effect,effectively control the blood glucose level of patients,reduce urinary albumin,and improve the micro-inflammatory state of the body and kidney function injury.

    参考文献
    相似文献
    引证文献
引用本文

何帅楠.补肾养肝汤治疗早期糖尿病肾病临床研究[J].新中医,2021,53(18):80-84

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-09-24
  • 出版日期:
文章二维码